GSC
RIGL icon

Ground Swell Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Ground Swell Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,094
Closed -$141K – 247
2024
Q2 		$141K Buy
+17,094
New +$179K 0.11% 83
2014
Q3 		$10K Buy
+495
New +$14K 0.02% 989

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ground Swell Capital's RIGL Position: Q3 2024 in Review

Ground Swell Capital sold out of Rigel Pharmaceuticals (RIGL) in Q3 2024, closing a stake of 17,094 shares — an estimated $141K sold.

Ground Swell Capital first reported a position in RIGL in Q3 2014 and held it in 2 quarters. The position peaked at $141K in Q2 2024. 93 funds tracked by Wall St. Rank hold RIGL as of Q3 2024.

  • Ground Swell Capital reported no remaining Rigel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ground Swell Capital sold 17,094 Rigel Pharmaceuticals shares in Q3 2024, an estimated $141K.
  • Ground Swell Capital first reported a position in Rigel Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Ground Swell Capital's Rigel Pharmaceuticals position peaked at $141K in Q2 2024.
  • 93 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2024.

Based on Ground Swell Capital's 13F filing for Q3 2024, filed 29 Oct 2024.